De-yun Luo
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
A nomogram construction and multicenter validation for predicting overall survival after fruquintinib application in patients with metastatic colorectal cancer: a multicenter retrospective study.
Journal: Therapeutic advances in gastroenterology
Published: March 28, 2024
Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third-line therapy in patients with refractory metastatic colorectal cancer: A real-world propensity score matching study.
Journal: Journal of evidence-based medicine
Published: February 29, 2024
Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study.
Journal: The oncologist
Published: December 27, 2020
S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.
Journal: The oncologist
Published: September 09, 2018
Clinical significance of serum CA125 in diffuse malignant mesothelioma.
Journal: SpringerPlus
Published: January 07, 2016
Prognostic factors of intraperitoneal chemotherapy for peritoneal carcinomatosis of gastric cancer: A retrospective study from a single center.
Journal: Oncology letters
Published: February 10, 2015
Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.
Journal: Anti-cancer drugs
Published: April 11, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026